Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis
NCT04923464 · View on ClinicalTrials.gov ↗
Study Summary
This study will evaluate the performance of wearable technology in cystic fibrosis (CF) participants taking commercial Elexacaftor (ELX)/Tezacaftor (TEZ)/Ivacaftor (IVA) utilizing a fully decentralized trial design.
Conditions Studied
Study Locations (17)
Other
- Birmingham Heartlands Hospital — Birmingham
- Royal Devon and Exeter Hospital — Exeter
- St. James University Hospital — Leeds
- Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital — London
- Wythenshawe Hospital — Manchester
- Southampton General Hospital — Southampton
Colorado
- National Jewish Health — Denver
Connecticut
- Yale New Haven Hospital — New Haven
Florida
- Central Florida Pulmonary Group, P.A. — Orlando
Illinois
- Children's Hospital of Illinois at OSF Saint Francis Medical Center, Cystic Fibrosis Center — Peoria
Massachusetts
- Massachusetts General Hospital Cystic Fibrosis Center Clinical Rsearch Center — Boston
Missouri
- Washington University School of Medicine — St Louis
New Jersey
- Morristown Medical Center — Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2021-12-20 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04923464
The ClinicalTrials.gov registry entry for NCT04923464 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 82 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04923464 reports 17 study locations spanning 12 distinct geographic areas — top geographies include Other, Colorado, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04923464 about?
NCT04923464 is a clinical study titled "A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis". This study will evaluate the performance of wearable technology in cystic fibrosis (CF) participants taking commercial Elexacaftor (ELX)/Tezacaftor (TEZ)/Ivacaftor (IVA) utilizing a fully decentralized trial design.
What is the current status of trial NCT04923464?
This trial is currently completed. The enrollment target is 51 participants. The study started on 2021-06-30. Estimated completion is 2021-12-20.
What conditions does trial NCT04923464 study?
This clinical trial studies the following conditions: Cystic Fibrosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT04923464?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 82 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04923464 being conducted?
This trial has 17 study locations across Colorado, Connecticut, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.